Oct. 28, 2013
/PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Prostate Cancer Drug Pathway Analyzer 2013
Extra value: One year of free online updates included with this product
There are today at least 374 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 248 drug targets that are included in this drug-pathway analyzing tool. No less than 244 of these have been recorded with mutations and 45 drug targets have mutations which have been causally implicated in cancer.
- BioCarta# 244 Pathways- KEGG# 182 Pathways- NCI-Nature# 243 Pathways- NetPath# 32 Pathways
Marketed# 30Pre-registration# 2Phase III# 20Phase II# 155Phase I# 79Preclinical# 121No Data# 4Suspended# 6Ceased# 180
The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.
For this reason BioSeeker, a leader in pipeline analytics, has constructed this high-level drug-pathway analyzer which lets you interact with the prostate cancer pipeline in a whole different than way than you ever done before. Its capabilities moves you beyond powerful competitive intelligence to an opportunity seeking tool which lets you, by means of both present and emerging scientific knowledge, analyze the prostate cancer pipeline for interesting compounds which affect and/or fit your purposes, may it be benchmarking, in/out-licensing, combination therapy options, drug repositioning, indication expansion etc.